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Abstract
Purpose The COVID-19 pandemic is placing unprecedented demand upon critical care services for invasive mechanical 
ventilation. There is current uncertainty regarding the role of tracheostomy for weaning ventilated patients with COVID-19 
pneumonia. This is due to a number of factors including prognosis, optimal healthcare resource utilisation, and safety of 
healthcare workers when performing such a high-risk aerosol-generating procedure.
Methods Literature review and proposed practical guideline based on the experience of a tertiary healthcare institution with 
195 critical care admissions for COVID-19 up until 4th April 2020.
Results A synthesis of the current international literature and reported experience is presented with respect to prognosis, 
viral load and staff safety, thus leading to a pragmatic recommendation that tracheostomy is not performed until at least 
14 days after endotracheal intubation in COVID-19 patients. Practical steps to minimise aerosol generation in percutaneous 
tracheostomy are outlined and we describe the process and framework for setting up a dedicated tracheostomy team.
Conclusion In selected COVID-19 patients, there is a role for tracheostomy to aid in weaning and optimise healthcare 
resource utilisation. Both percutaneous and open techniques can be performed safely with careful modifications to technique 
and appropriate enhanced personal protective equipment. ORL-HNS surgeons can play a valuable role in forming tracheos-
tomy teams to support critical care teams during this global pandemic.
Keywords SARS-CoV-2 · Novel coronavirus · COVID-19 · Tracheostomy · Mechanical ventilation
Introduction
The COVID-19 pandemic is placing unprecedented demands 
upon critical care services across the world. As of the 10th 
April 2020, there are currently 70,272 confirmed cases in 
the UK and over 1.6 million globally, with around half these 
total cases in Europe [1]. Current evidence from China sug-
gests that between 9.8 and 15.2% of patients will require 
invasive mechanical ventilation or extracorporeal mem-
brane oxygenation (ECMO) [2–4]. On 10th April 2020, the 
intensive care national audit and research centre (ICNARC) 
published their second report on data from 3883 confirmed 
COVID-19 admissions to critical care in England, Wales and 
Northern Ireland. Of these, 1689 were completed episodes 
with 871 deaths and 818 discharged from critical care, giv-
ing a present mortality rate of 51.6% for those requiring 
critical care admission [5]. As a high consequence infectious 
disease unit, our institution was one of the first in the UK to 
treat confirmed COVID-19. As of 4th April 2020, we have 
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had 195 admissions to critical care with a mortality rate of 
33.0%.
The insertion of a tracheostomy after around 7–10 days 
of invasive mechanical ventilation is generally considered 
a standard of care due to potential to reduce the duration 
of mechanical ventilation and length of stay on intensive 
care [6, 7]. The National Confidential Enquiry into Patient 
Outcome and Death (NCEPOD) study estimated that around 
12,000 adult tracheostomies a year were performed in Eng-
land, Wales and Northern Ireland for such indications in 
2014 [8]. Assuming the incidence is the same across Europe 
(0.2/1,000) then this represents a total of around 100,000 
tracheostomies per year. Approximately 70% of these are 
estimated to be performed by intensivists on intensive care 
units (ICU) using percutaneous dilatation techniques in the 
UK, which reflects a shift in practice since the introduction 
of this technique in 1985 [8].
Genomic analysis of SARS-CoV-2 has determined it to 
be of a different clade to the betacoronaviruses associated 
with human severe acute respiratory syndrome (SARS) and 
Middle East respiratory syndrome (MERS); however, it is 
well recognised as causing similar respiratory symptoms 
secondary to a viral pneumonia and in some cases the pro-
gression to acute respiratory distress syndrome (ARDS) [4]. 
The classical radiological appearances are of patchy ground 
glass opacification and consolidation that may affect mul-
tiple lobes and progress to diffuse and dense consolidation. 
Published studies so far suggest in the early stages of disease 
there is patchy inflammatory infiltrate, oedema and proteina-
ceous exudate, with one autopsy study in a patient that died 
of COVID-19 showing bilateral diffuse alveolar damage 
with cellular fibromyxoid exudates and interstitial inflam-
matory infiltrates [9, 10]. The acute lung injury and resultant 
respiratory failure are responsible for the high levels of inva-
sive mechanical ventilation required for COVID-19 patients.
The COVID-19 pandemic presents unique challenges 
when considering performing a tracheostomy for such 
patients for a number of reasons. First, the prognosis of this 
novel disease is not yet fully understood but mortality rates 
for those requiring critical care are in the region of 50% 
[2, 5], which is considerably higher than non-COVID viral 
pneumonia (22.4%) [5]. This poses a risk of performing 
futile procedures if a tracheostomy is considered too early. 
Second, the duration of detectable viral load and correlation 
with transmission rates during aerosol generating procedures 
is not yet specifically known. Evidence from China showed 
infection rates of 3.8% amongst healthcare personnel treat-
ing COVID-19 patients [2] but at present, the infection rate 
related to tracheostomy insertion is unknown. There is no 
evidence to support a specific technique for tracheostomy 
insertion in terms of minimising risk of healthcare personnel 
exposure to airborne droplets.
Whilst post-intubation laryngo-tracheal stenosis is a well-
known risk of prolonged endotracheal intubation, there is 
no evidence it is significantly reduced in patients treated 
with early tracheostomy (typically less than 10 days). It is 
too soon to know if there will be any difference amongst 
the COVID-19 cohort of patients [11, 12]. The incidence of 
ventilator-associated pneumonia and overall mortality does 
not improve with early tracheostomy in non-COVID popula-
tions [13–17].
Our institution’s experience is that a significant propor-
tion of patients admitted for mechanical ventilation are 
weaning and being successfully extubated between days 
5 and 10. This is reflected in our median (IQR) length of 
stay for survivors of 5 (2.7, 11.8) days and supported by the 
ICNARC report with a median (IQR) duration of advanced 
respiratory support of 7 (4, 10) days for 1689 confirmed 
COVID-19 cases. These are mostly younger patients with 
less co-morbidity [5]. It is also our experience that those 
who do not get better at this point may have a poor overall 
prognosis.
Based upon learning from China and Italy, the basic 
principles of our local strategies and protocols have sur-
rounded early intubation  (Fi02 > 0.4 with increased work of 
breathing) for younger patients with less co-morbidity and 
advanced care planning with early decisions regarding ceil-
ing of care for those least likely to derive benefit. Decision-
making around co-morbidity and critical care admission is 
guided by the clinical frailty score in patients older than 65 
as recommended by the National Institute for Health and 
Care Excellence (NICE), and individualised decisions are 
made for those aged under 65 [18]. This may reduce the 
overall number of the elderly and those with multiple co-
morbidities that would be more likely to require prolonged 
mechanical ventilation with little or no derived benefit.
Despite this, there will still be a select cohort of patients 
who will need longer time to wean and where tracheos-
tomy will be indicated. The benefits can include offering a 
‘sealed’ system for ongoing respiratory support. This may 
be preferable to primary extubation with a high risk of fail-
ure, a requirement for high-flow oxygen or non-invasive 
ventilation. Tracheostomy also allows a lower requirement 
for sedation thereby facilitating less invasive nursing care; 
fewer infusion pumps, and the potential for their care to be 
overseen by non-intensive care trained nursing staff [19]. It 
is well established that shortening the duration of sedation 
required minimises risk and duration of associated complica-
tions, including delirium, and has been shown to reduce the 
overall length of stay [20].
A tracheostomy in this cohort of patients brings with it a 
risk to the healthcare professionals involved both during the 
actual procedure and in the post-procedure period wherein 
the patients’ tracheostomy needs to be managed.
European Archives of Oto-Rhino-Laryngology 
1 3
In a time where healthcare resources are being placed 
under a huge strain, there is likely to be a proactive but selec-
tive role for tracheostomy. This will benefit both the patient, 
and provide net benefit for population health resources.
The aim of this paper is to review the current interna-
tional literature to synthesise a proposed practice model, 
guideline, and describe the pre-emptive setup and training 
of a dedicated tracheostomy team.
Most importantly, we outline proposed steps that can be 
taken to minimise aerosol generation for percutaneous tra-
cheostomy in COVID-19 patients, as we could find no guid-
ance in the existing literature describing this.
Methods
We performed a literature review of tracheostomies during 
the current and previous pandemics consisting of a Pub-
Med search with the terms tracheostomy and Coronavirus, 
COVID-19, SARS-CoV-2, SARS, MERS. Papers published 
between 2000 and April 2020 were critically appraised with 
respect to specific considerations: timing, viral load, staff 
safety and technique. In addition all publications referencing 
Coronavirus, COVID-19 and SARS-CoV-2 were screened 
for relevant content. All COVID-19-related guidance pub-
lished from oto-rhino-laryngological societies was also 
reviewed for relevant content.
Clinical considerations and risks
Timing
Evidence from Wuhan demonstrated the median time from 
hospital admission to death was 5 days [21]. In Lombardy, 
the median time (IQR) from critical care admission to death 
has been reported as 7 (5–11) days [22] and in the UK it is 
currently 6 (3–9) days [5]. Therefore, it seems prudent to 
wait until the prognosis is clear before doing a futile proce-
dure that could expose healthcare workers to unnecessary 
risk. The American Academy of Otolaryngology-Head 
and Neck surgery currently recommends that tracheostomy 
should not be performed prior to 14 days of endotracheal 
intubation [23]. Anecdotal reports from colleagues in Spain, 
Italy and Austria suggest that these countries are also adopt-
ing a local policy of around 14 days before undertaking 
tracheostomy.
Whilst there is no evidence as to the optimal timing of 
tracheostomy, when considering the current literature with 
respect to the disease process, the best use of healthcare 
resources, and staff safety, this time frame appears to be a 
prudent starting point. Waiting for 14 days will help ensure 
the indication for the tracheostomy is to treat the ongoing 
lung injury rather than the effects of the infection itself and 
is likely to minimise unnecessary interventions.
Viral load and COVID‑19 PCR status
At this stage, there is no evidence to confirm if the viral load 
of a patient at a specific time point correlates with transmis-
sion risk to healthcare workers. It has, however, been shown 
that viral load does not correlate well with severity of symp-
toms in an individual, so not all those critically ill will have 
high viral loads [24].
Initial studies have shown that viral loads from nasal and 
throat swabs were highest in the early phase of the disease, 
with clearance by days 9–15 [25, 26]. Evidence from China 
suggests viral loads in secretions remain detectable up to 
2–3 weeks after the onset of symptoms with a median of 
20 days and the longest case in their series lasted 37 days 
[27].
Both the US and Canadian guidelines strongly advise 
that patients should test negative for COVID-19 before pro-
ceeding with tracheostomy [23, 28]. It should be noted that 
the sensitivity of a single nasal and throat rt-PCR swab for 
COVID-19 has been estimated at 71% in studies [29], so a 
negative result should not give false reassurance to surgi-
cal teams that exposure risk has passed. In our experience, 
currently, there are not testing facilities in the UK to allow 
multiple tests on a single patient, and whilst not definitive, 
two negative tests may give more reassurance that risk to 
healthcare personnel is being minimised. In addition, the 
COVID-19 status may contribute to broader decision-mak-
ing around proceeding with a tracheostomy. The availability 
of repeat testing should be a priority for implementation to 
minimise operator risk.
The evidence thus far in terms of viral load risk would 
suggest that delaying tracheostomy to at least 14 days post-
intubation would represent the safest possible balance. Given 
the natural disease course, this would likely represent at least 
3 weeks since the onset of symptoms. However, it is possible 
there is an increased risk in the elderly or those with multi-
organ failure where viral loads seem to remain elevated for 
much longer. It has been hypothesised this persistence could 
be attributed to a lack of appropriate immune response in 
these patients [27].
Staff safety
Ensuring minimal exposure and risk to staff performing the 
procedure will be of paramount importance. Present guid-
ance recommends full personal protective equipment (PPE) 
for all aerosol-generating procedures including FFP3 mask, 
eye protection, fluid-repellent disposable surgical gown 
and gloves [30]. Powered air-purifying respirators (PAPRs) 
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reduce the risk of exposure more than FFP3 masks, but how 
much more is dependant upon the airflow setting [31]. A 
literature review of case series and reports from the SARS 
outbreak identified 23 tracheostomies performed where no 
healthcare personnel became infected. It was noted that in all 
cases PAPRs were used by the operating team [32]. There-
fore, it appears that this enhanced level of PPE represents 
the safest possible level of protection for staff and should be 
mandatory when performing tracheostomy. In our institu-
tion, PAPRs are available in ICU and theatres for our trache-
ostomy team. It is also mandatory for staff to receive PPE 
training as this can represent a source of contamination if 
not done correctly [30].
Procedure setting and location
The ideal location for performing a tracheostomy on a 
COVID-19 + patient is in a negative pressure side room or 
operating theatre [33]. This setting would be ideal but not 
always feasible due to their limited availability and resource 
implications in a pandemic. Most operating theatres in 
Europe are positive pressure so do not represent a preferred 
environment. It may be possible to convert existing thea-
tres to negative pressure rooms after discussion with local 
estate teams. Moreover, the implications, resources and risks 
associated with mobilising a ventilated, COVID-19 + patient 
from the intensive care to the operating theatre should be 
carefully considered.
Percutaneous tracheostomy (PT) is routinely performed at 
the bedside in intensive care unit (ICU). Unfortunately, the 
literature search did not reveal guidance specific to COVID-
19 + patients. After discussion with intensivists (DW, ST), 
it is our policy is to perform PT in the ICU setting in cases 
where the negative pressure side room will not be available. 
In the following section, we discuss the precautions of mini-
mising the aerosolization during tracheostomy.
Technique
In 2016, a systematic review by Brass et al. comparing per-
cutaneous and surgical tracheostomies (ST) did not find any 
difference in mortality or serious complications, there was, 
however, a lower rate of wound infections and scarring with 
PT [34]. There is currently no evidence to advise which pro-
cedure is less aerosol generating. However, during the SARS 
outbreak ST was favoured and felt to be beneficial due to less 
disruption to ventilation and avoidance of multiple entries to 
the trachea required with serial dilatations [32]. The single-
stage ‘Rhino’ dilator technique is the most common percuta-
neous technique in the UK, and avoids multiple entries [35].
In addition to the requirement to open the trachea under 
direct vision, the use of energy devices (e.g. bipolar cau-
tery or ultrasonic shears) to control bleeding during ST can 
lead to aerosolization [31]. The use of a bronchoscope for 
guidance in PT has the potential to increase aerosol gen-
eration due to the requirement to intermittently open the 
circuit under positive pressure ventilation. We use a sealed 
port for bronchoscopy and pause ventilation for insertion 
and removal to reduce risk of aerosolization. Percutaneous 
ultrasound is an alternative method of guidance for PT that 
avoids aerosol generation.
Ultimately, the decision on which technique to employ 
will be guided by local expertise and resources. The ENT-
UK guidance set out clear instructions on how to safely 
perform ST in COVID-19 + patients and it has been cited 
in multiple other guidelines issued by international bod-
ies since its release [23, 28, 36]. The key actions are sum-
marised in Fig. 1, which is taken from this guidance. The 
ENT-UK guidance also covers a wide range of considera-
tions valid to both ST and PT concerning planning and post-
procedural care.
There has been no prior description in the literature of 
how to minimise aerosol generation in PT. Therefore, we 
have outlined the considerations in Fig. 2, and some key 
points are highlighted:
• The use of a bronchoscope is not always necessary, but 
the use of catheter mount (flexible tube connector) with 
sealed port for bronchoscopy can minimise aerosol gen-
eration if it is required for guidance.
• The procedure is performed under deep sedation and full 
neuromuscular blockade.
• The initial step is to deflate the endotracheal tube (ETT) 
cuff and withdraw ETT under laryngoscopic vision until 
cuff is visualized at the level of the vocal cords. We rec-
ommend overinflating cuff to ensure no leak throughout 
the procedure (as described in ST).
• We advise clamping ETT and pausing ventilation (at end-
expiration) during these critical steps that are associated 
with increased risk of aerosol generation: changing cath-
eter mount, repositioning ETT cuff to the level of the 
vocal cords, and removal of large rhino dilator.
• Tracheal puncture site should be covered with a swab 
throughout the procedure to reduce aerosol spread.
Team training and establishment
ENT-UK has also recommended that dedicated teams be 
established to carry out these procedures with the specific 
skills and expertise necessary to perform this as safely 
and in as timely manner as possible [36]. One considera-
tion for such team is having enough personnel to minimise 
repeated exposure to high levels of aerosol. A study from 
the SARS outbreak suggested repeated exposure on con-
secutive shifts can increase risk of healthcare-associated 
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transmission [37]. We could not find any evidence as to 
the risk related to the number of procedures performed in 
a single shift.
With safety at the core of our team-based approach; we 
have initially set out that our tracheostomy team members 
will not work more than 1 day per week in this role, and 
not perform more than two tracheostomies per day. Teams 
will initially be operational twice a week on non-consecutive 
days with staff on a rotational basis to minimise exposure 
whilst ensuring consistency in expertise levels across the 
week. In addition, all team members will be provided with 
enhanced PPE to include PAPRs.
In our institution, representation from anaesthetics, inten-
sive care (DW/ST) and otorhinolaryngology-head and neck 
surgery (ORL-HNS) have formed a cross-speciality work-
ing group to design the tracheostomy team and develop the 
best possible guidance using shared expertise. This will also 
support multi-disciplinary decision-making around timing 
Fig. 1  ENT-UK Guidance 
for COVID-19 tracheostomy. 
Reproduced with the permission 
of the authors
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and appropriateness of tracheostomy. Within the ORL-HNS 
department, current levels of expertise and experience for 
both percutaneous and surgical techniques were established 
for both consultants and senior trainees to help identify 
appropriate team leaders and ensure adequate skill levels. 
Cadaveric refresher training was provided over a 1-day ses-
sion to 25 personnel from the ORL-HNS department. The 
team had an opportunity to practice the percutaneous tech-
nique in line with our action cards twice each. During this 
day, we were also able to create an instructional video to 
support learning and ensure our teams are well rehearsed in 
the COVID-19 percutaneous technique. A link to the edited 
video is available here: https ://rise.artic ulate .com/share 
/7lfMu 5dnIB bNMgt S4JIZ P96GH FdyEW OH#/.
Our core tracheostomy team consists of
• two anaesthetists to manage airway ± bronchoscopy;
• two operators (ORL-HNS surgeon or intensive care phy-
sician);
• intensive care nurse;
• runner/safety officer.
Fig. 1  (continued)
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In the event of an emergency, each team will have a 
nominated leader identified prior to the procedure. Where 
possible, it is envisaged that PT will be the technique of 
choice and performed at the bedside. However, in specific 
circumstances a ST may need to be performed in an operat-
ing theatre.
Indications for tracheostomy
Based on the current literature and our experience the 
authors have agreed initial selection criteria for use in our 
institution. These are set out in Table 1.
Guidelines should remain under constant review as higher 
level evidence of this novel disease and its outcomes from 
critical care emerge. They propose a robust but concise list 
to support decision-making in this challenging area.
Fig. 1  (continued)
 European Archives of Oto-Rhino-Laryngology
1 3
Prospective analysis and audit of outcomes
To rapidly learn and improve audit and outcomes of prac-
tice will be essential and we propose a mandatory minimum 
audit dataset in Table 2 that can allow local and regional net-
works to collaborate to improve the knowledge about what 
will serve this cohort of patients best.
Post‑procedural care and rehabilitation
The focus of early post-procedural care is to ensure mini-
misation of aerosol generation risk to healthcare workers 
and other patients until any risk has passed. Early measures 
include keeping the cuff inflated, use of in-line suction, and 
avoidance of humidified oxygen if possible. Cuff deflation, 
changing of tracheostomy tube and progress on a decannula-
tion protocol should be deferred until the patient is COVID-
19 negative where possible. The provision for nursing and 
rehabilitation of patients once discharged from the ICU 
will also need to be considered. The cohorting of patients 
Fig. 1  (continued)
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Fig. 2  Percutaneous tracheostomy action card
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recovering from COVID-19 with tracheostomies onwards 
with appropriately trained nursing staff is desirable. A num-
ber of other considerations and advice for post-procedural 
care specific to COVID-19 are detailed in the national tra-
cheostomy safety project and ENT-UK guidance [18, 33].
Summary
These proposals provide a robust framework on which to 
base delivery of tracheostomy services for critical care units 
during the COVID-19 pandemic, this can prove an invalu-
able resource as other countries across Europe and the rest 
of the world could soon be faced with a surge in demand.
At present, there is no high-level evidence beyond case 
series upon which to make definitive recommendations, but 
we have based our proposed guidelines upon consensus from 
the currently available literature to form a pragmatic and safe 
approach. There is no doubt that as more rapidly emerging 
higher level evidence becomes available, our recommenda-
tions will be refined and improved.
The decision to perform tracheostomy in these patients 
requires careful consideration, planning and regular scrutiny 
if it is going to be of net benefit to patients and critical care 
services in terms of optimising healthcare resource utilisa-
tion, ensuring patient and staff safety and providing optimal 
long-term outcomes.
Urgent planning, training and collaborative data collec-
tion will be vital, and ORL-HNS surgeons have the potential 
to offer a valuable role in supporting critical care teams with 
this service at a very challenging time.
Key recommendations
• Performing tracheostomy for prolonged invasive mechan-
ical ventilation on COVID-19 must be very carefully 
considered.
• The mortality for patients ventilated with COVID-19 is 
around 50% and tracheostomy should not be performed 
until the prognosis is deemed favourable.
• The current literature and consensus opinion suggest that 
tracheostomy should only be considered after 14 days of 
invasive mechanical ventilation when the patient is still 
not suitable for extubation.
• All staff performing tracheostomy in COVID-19 patients 
must be equipped with enhanced PPE including PAPRs.
• There is currently no evidence whether percutaneous or 
surgical tracheostomy is less aerosol generating.
• Deep sedation, complete neuromuscular blockade and 
endotracheal tube cuff hyperinflation should be employed 
for all tracheostomy procedures.
• Strategies to reduce aerosol generation in percutaneous 
tracheostomies include avoiding the use of bronchoscope 
(or using catheter mount with sealed port), pausing ven-
tilation at end-expiration and clamping the endotracheal 
tube before key steps in the procedure (changing catheter 
Table 1  Selection criteria for COVID-19 Tracheostomy
Fi02 fraction of inspired oxygen, PEEP positive end-expiratory pressure
Patients may be considered for tracheostomy on or after day 14 of intubation where there is an ongoing requirement for mechanical ventilation
The patient’s case should have been reviewed by at least two intensive care consultants’/senior specialists and the procedure deemed appropriate
Technique and location agreed between intensive care and ORL-HNS team
Ventilation requirements appropriate (suggest  Fi02 ≤ 50%, PEEP ≤ 10)
In patients where the prognosis is not clear, they are older (> 70), and/or have multi-organ failure; the decision to proceed should be deferred
Where there are contraindications to intervention (e.g. severe coagulopathy), the decision to proceed to tracheostomy should be delayed further 
beyond 14 days
Most recent COVID-19 testing status determined (not universally available—priority for implementation)
Table 2  Minimum audit dataset
BMI body mass index, APACHE Acute Physiologic Assessment and 
Chronic Health Evaluation, CPAP continuous positive airways pres-
sure
Patient age, sex, co-morbidities, BMI
APACHE II Score
Days post-intubation procedure performed
COVID status at the time of procedure (most recent test result and 
date)
Technique and location
Members of tracheostomy team and any possible COVID-19 trans-
mission
Procedural complications
Days post-tracheostomy when sedation ceased
Days post-tracheostomy when invasive ventilation ceased (moved to 
non-invasive ventilation like CPAP)
Days post-tracheostomy discharged from critical care
Days post-tracheostomy discharged from hospital or died
Cause of death (if applicable)
Days to decannulation
Total length of stay
European Archives of Oto-Rhino-Laryngology 
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mount, withdrawing tube, removing dilators, inserting 
tracheostomy tube).
• Early planning and staff training is essential and can 
ensure adequate resources and expertise to support the 
increase in demand whilst minimising exposure risk for 
healthcare personnel.
• Prospective analysis and audit of outcomes are essential 
to rapidly learn and improve outcomes for this cohort of 
patients.
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